Last updated: June 17, 2026
Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. (docket 1:21-cv-00900) is a US Hatch-Waxman patent enforcement dispute tied to Lupin’s ANDA entry strategy against an Otsuka-branded product. The case was filed in 2021 and proceeds through standard Paragraph IV litigation stages (pleadings, validity/infringement analysis, and settlement or adjudication depending on the parties’ posture). The provided docket identifier is sufficient to anchor a procedural summary, but not sufficient to produce a patent-by-patent, Orange Book–linked infringement and validity analysis, or a timeline of key claim-construction and dispositive events, because the record-level details (asserted patents, Orange Book listing, FDA approval date, ANDA filing/notice dates, and final outcome) are not included in the prompt.
What is the case timeline for Otsuka Pharmaceutical v. Lupin (1:21-cv-00900)?
A docket-number-only query cannot support a defensible timeline with dates for:
- ANDA filing date and Paragraph IV notice date
- Complaint filing date and service
- Markman/claim construction events
- Expert report deadlines
- Summary judgment motions
- Trial date or settlement timing
- Dismissal status or final judgment entry
What patents are asserted in Otsuka v. Lupin 1:21-cv-00900?
A litigation-number-only query cannot support a complete or accurate asserted-patent list. Hatch-Waxman cases typically specify:
- Orange Book listed patents for the reference listed drug (RLD), split across formulation, method-of-use, and composition-of-matter categories
- Specific asserted claims and product labels (indication and dosing)
- Infringement theories (literal infringement vs. equivalents)
- Invalidity theories (102/103 obviousness, 112, 101, prior art publications, and written description/enablement)
Without the complaint or docket documents, any enumeration of patent numbers, claim numbers, or invalidity grounds would be unreliable.
How do courts analyze infringement and validity in Hatch-Waxman cases like Otsuka v. Lupin?
In Paragraph IV litigation, the practical analytic framework is:
- Claim construction (usually the center of gravity for product-focused disputes)
- Infringement mapping to the proposed ANDA drug label and manufacturing process as constrained by ANDA equivalence positions
- Invalidity grounds tied to cited references (publications, patents, and sometimes applicant-specific disclosures)
- Statutory and procedural constraints: 35 USC 271(e)(2), standing/technical issues, and information access limits
A case-specific view requires the asserted patents and the court’s rulings on claim scope and validity.
What does an Orange Book status check usually show for cases like this?
For ANDA litigations, the Orange Book typically drives:
- Which patents are “listed” for the RLD and whether they are the basis of the enforcement
- Remaining patent terms and pediatric exclusivity interactions
- Whether the generic filing triggers a 30-month stay and whether that stay is modified by litigation outcome
But the RLD name, NDC, listed patent numbers, and listed expiration dates are not provided. Without that, an Orange Book–linked status summary would be incomplete.
When does Otsuka’s exclusivity end versus Lupin’s potential generic entry risk?
A workable exclusivity-to-entry risk analysis requires:
- RLD first approval date
- Patent expiration dates for each asserted Orange Book patent
- Any granted exclusivity extensions (including pediatric exclusivity)
- 30-month stay status and whether it triggered or lapsed
- Settlement agreement terms (if any) that cap entry dates
None of those inputs are present, so the exclusivity calendar cannot be built from the prompt.
What is the commercial and licensing impact of Otsuka v. Lupin?
In Hatch-Waxman disputes, commercial outcomes usually hinge on one or more of:
- A final judgment allowing or blocking ANDA launch
- A covenant-not-to-sue structure (often with market-entry date restrictions)
- A stipulated dismissal with terms that functionally align launch dates
- Residual non-enjoined design-around or “skinny” labeling opportunities
A credible licensing or market impact summary requires the disposition and any settlement entry-date language from the docket.
How strong is the Otsuka patent estate in this litigation?
Strength analysis must be grounded in:
- Claim scope as construed
- Litigation posture (infringement concessions, summary judgment rulings)
- Prior art quality and anticipation/obviousness fit
- 112 issues tied to specification disclosure of key limitations
- Any early rulings indicating survivability of asserted claims
Without asserted patents, court orders, or outcomes, no strength rating can be produced without speculation.
What generic entry risks exist for Lupin after 1:21-cv-00900?
Post-litigation risk depends on:
- Whether Lupin prevailed on all asserted patents
- Whether claims were narrowed so that Lupin’s product is no longer infringing
- Whether there was a settlement that enjoins entry until a specific date
- Whether other listed patents remain enforceable but unasserted
No disposition data is included, so the entry risk cannot be calculated.
What manufacturing and formulation/IP barriers could apply to Otsuka’s product category?
Formulation or method-of-use cases can turn on:
- Drug substance form (polymorph/solvate/hydrate)
- Excipients and manufacturing parameters
- Controlled-release or bioavailability criticality
- Label-controlled indication limitations
This analysis requires knowing the product and asserted patent categories, which are not included.
What is the likely procedural outcome path for a case filed in 2021 like this?
Typical outcomes include:
- Settlement and stipulated dismissal
- Summary judgment or partial judgment on infringement/invalidity
- Final judgment with appeal
- Ongoing proceedings where claim construction or discovery remains active
But the actual end-state (settled vs. adjudicated) cannot be determined from docket number alone.
Key Takeaways
- The prompt provides the docket identifier (1:21-cv-00900) but not the complaint contents, asserted patents, RLD/Orange Book listings, or disposition orders needed for a litigation-grade summary.
- A patent-by-patent infringement/validity analysis, exclusivity-to-entry calendar, and commercial impact assessment require record-level details not included here.
- Any attempt to name asserted patents, list court holdings, or state entry dates would not be grounded in the supplied information.
FAQs
- What typically triggers a 30-month stay in ANDA Paragraph IV cases like Otsuka v. Lupin?
- How do settlement agreements in Hatch-Waxman cases usually affect launch timing and covenants-not-to-sue?
- What categories of patents (formulation, method-of-use, composition-of-matter) are most likely asserted in Otsuka-style enforcement actions?
- How does FDA labeling (“skinny label” vs. full label) influence infringement scope in Paragraph IV litigation?
- What court order types (claim construction, summary judgment, final judgment) most materially change generic entry risk?
References
- Federal Trade Commission. (n.d.). Patent litigation under the Hatch-Waxman Act: overview and process.
- US Food and Drug Administration. (n.d.). Hatch-Waxman ANDA and Orange Book framework.
- US District Court docket for Otsuka Pharmaceutical Co., Ltd. v. Lupin Limited, 1:21-cv-00900. (2021).
